Little Andrew S, Shetter Andrew G, Shetter Mary E, Bay Curt, Rogers C Leland
Division of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA.
Neurosurgery. 2008 Nov;63(5):915-23; discussion 923-4. doi: 10.1227/01.NEU.0000327689.05823.28.
The long-term outcome of patients treated with gamma knife radiosurgery (GKRS) for typical trigeminal neuralgia has not been fully studied. We evaluated 185 patients who underwent their first GKRS treatment between 1997 and 2003 at the Barrow Neurological Institute.
Follow-up was obtained by surveys and review of medical records. Outcomes were assessed by the Barrow Neurological Institute Pain Intensity Score and Brief Pain Inventory. The most common maximum dose was 80 Gy targeted at the root entry zone. Outcomes are presented for the 136 (74%) patients for whom more than 4 years of clinical follow-up data were obtained.
Treatment failed in 33% of the cohort within 2 years, but only an additional 1% relapsed after 4 years. Actuarial analysis demonstrated that 32% of patients were pain-free off medication and 63% had at least a good outcome at 7 years. When GKRS was used as the primary treatment, 45% of the patients were pain-free at 7 years. In contrast, 10% of patients in whom previous treatment had failed were pain-free. When needed, salvage therapy with repeat GKRS, microvascular decompression, or percutaneous lesioning was successful in 70%. Posttreatment facial numbness was reported as very bothersome in 5%, most commonly in patients who underwent another invasive treatment. After GKRS, 73% reported that trigeminal neuralgia had no impact on their quality of life.
GKRS is a reasonable long-term treatment option for patients with typical trigeminal neuralgia. It yields durable pain control in a majority of patients, as well as improved quality of life with limited complications and it does not significantly affect the efficacy of other surgical treatments, should they be needed.
对于接受伽玛刀放射外科治疗(GKRS)的典型三叉神经痛患者的长期预后尚未进行充分研究。我们评估了1997年至2003年间在巴罗神经学研究所首次接受GKRS治疗的185例患者。
通过调查和查阅病历获得随访信息。采用巴罗神经学研究所疼痛强度评分和简明疼痛量表评估预后。最常用的最大剂量是80 Gy,靶点为神经根入区。本文呈现了136例(74%)患者的预后情况,这些患者获得了超过4年的临床随访数据。
在2年内,该队列中有33%的患者治疗失败,但4年后仅有另外1%的患者复发。精算分析表明,32%的患者在停药后无痛,63%的患者在7年时至少有良好的预后。当GKRS作为主要治疗方法时,45%的患者在7年时无痛。相比之下,先前治疗失败的患者中有10%无痛。必要时,重复GKRS、微血管减压或经皮损伤等挽救治疗的成功率为70%。5%的患者报告治疗后面部麻木非常困扰,最常见于接受过另一种侵入性治疗的患者。GKRS治疗后,73%的患者报告三叉神经痛对其生活质量没有影响。
GKRS是典型三叉神经痛患者合理的长期治疗选择。它能使大多数患者持久控制疼痛,改善生活质量,并发症有限,并且如果需要,不会显著影响其他外科治疗的疗效。